Panelists discuss first-line treatment strategies and best practices for managing non–clear cell renal cell carcinoma, highlighting clinical trial data on efficacy and adverse events, and exploring multidisciplinary approaches to mitigate toxicities and enhance patient outcomes.
EP. 1: Overview of Non–Clear Cell Renal Cell Carcinoma
September 18th 2025Panelists discuss first-line therapy for non–clear cell renal cell carcinoma, emphasizing its diverse histologies, the challenges posed by limited clinical trial data, and the importance of molecular diagnostics and multidisciplinary strategies to guide personalized treatment.
EP. 2: First-Line Treatment Options
September 18th 2025Panelists discuss first-line treatment strategies for metastatic non–clear cell renal cell carcinoma, highlighting the shift from broad, subtype-agnostic approaches to histology-specific and biomarker-driven therapies, including evolving combinations of TKIs and immunotherapy tailored to tumor biology.
EP. 3: SUNNIFORECAST Trial Review
September 25th 2025Panelists discuss findings from a landmark European phase 3 trial showing improved overall survival with ipilimumab and nivolumab versus standard therapies in non–clear cell renal cell carcinoma, supporting the role of immune-based combinations across histologic subtypes and reinforcing the need for subtype-specific treatment strategies.
EP. 4: Cabozantinib Plus Nivolumab Trial Review
September 25th 2025Panelists discuss results from a phase 2 study of nivolumab plus cabozantinib in non–clear cell renal cell carcinoma, highlighting promising efficacy but notable treatment discontinuation rates likely linked to patient complexity, underscoring the need for further research on TKI-IO combinations in this diverse population.
EP. 5: KEYNOTE-B61 Trial Review
October 2nd 2025Panelists discuss the KEYNOTE-B61 phase 2 trial of lenvatinib and pembrolizumab in non–clear cell renal cell carcinoma, highlighting its promising response rates, durable remissions, and subtype-specific outcomes, while emphasizing the need for further research to refine treatment approaches across diverse histologies.
EP. 6: Clinical Trials in Review
October 2nd 2025Panelists discuss the evolving clinical trial landscape in non–clear cell renal cell carcinoma, highlighting ongoing studies of combination therapies integrating TKIs and immuno-oncology agents, the challenges of rare subtypes, and the critical role of trials and support networks in advancing personalized treatment options.
EP. 7: Patient Case 1: Papillary
October 9th 2025Panelists discuss the case of a metastatic papillary kidney cancer patient, emphasizing the importance of balancing efficacy and tolerability in frontline therapy selection, incorporating molecular profiling, and considering immune-based combinations alongside targeted agents within a personalized, multidisciplinary care framework.
EP. 8: Patient Case 2: Chromophobe
October 9th 2025Panelists discuss the complexities of managing metastatic chromophobe renal cell carcinoma in a high-risk patient, emphasizing the role of molecular testing, limited but evolving therapeutic options including VEGF and mTOR inhibitors and immunotherapy, and the urgent need for subtype-specific clinical trials to guide personalized care.
EP. 9: Future of Non–Clear Cell Renal Cell Carcinoma
October 9th 2025Panelists discuss the rapidly evolving landscape of non–clear cell renal cell carcinoma, emphasizing the shift toward subtype-specific clinical trials, the critical role of next-generation sequencing and germline testing in guiding personalized treatment, and the importance of ongoing research collaborations to advance precision medicine and improve patient outcomes.